|
1) Cines DB, Blanchette VS. Immune thrombo-cytopenic purpura. N Engl J Med. 2002; 346: 995-1008
|
|
|
|
2) 冨山佳昭. 特発性血小板減少性紫斑病. 臨血. 2008; 49: 1298-305
|
|
|
|
|
3) Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009; 113: 2386-93
|
|
|
|
|
|
4) McMillan R, Tani P, Millard F, et al. Platelet-associated and plasma anti-glycoprotein autoantibodies in chronic ITP. Blood. 1987; 70: 1040-5
|
|
|
|
|
|
5) Tomiyama Y, Kosugi S. Autoantigenic epitopes on platelet glycoproteins. Int J Hematol. 2005; 81: 100-5
|
|
|
|
|
|
6) McMillan R, Nugent D. The effect of antiplatelet autoantibodies on megakaryocytopoiesis. Int J Hematol. 2005; 81: 94-9
|
|
|
|
|
|
7) Kurata Y, Hayashi S, Kiyoi T, et al. Diagnostic value of tests for reticulated platelets, plasma glycocalicin, and thrombopoietin levels for discriminating between hyperdestructive and hypoplastic thrombocytopenia. Am J Clin Pathol. 2001; 115: 656-64
|
|
|
|
|
|
8) Portielje JE, Westendorp RG, Kluin-Nelemans HC, et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001; 97: 2549-54
|
|
|
|
|
|
9) Vianelli N, Galli M, de Vivo A, et al. Efficacy and safety of splenectomy in immune thrombo-cytopenic purpura: long-term results of 402 cases. Haematologica. 2005; 90: 72-7
|
|
|
|
|
|
10) McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood. 2004; 104: 956-60
|
|
|
|
|
|
11) George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996; 88: 3-40
|
|
|
|
|
|
12) British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003; 120: 574-96
|
|
|
|
|
|
13) Fujimura K, Kuwana M, Kurata Y, et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura？ Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol. 2005; 81: 162-8
|
|
|
|
|
|
14) Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood. 2009; 113: 1231-40
|
|
|
|
|
|
15) Asahi A, Nishimoto T, Okazaki Y, et al. Helicobacter pylori eradication shifts monocyte Fcγ receptor balance toward inhibitory FcγRIIB in immune thrombocytopenic purpura patients. J Clin Invest. 2008; 118: 2939-49
|
|
|
|
|
|
16) McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med. 1997; 126: 307-14
|
|
|
|
|
|
17) Kuter DJ. New thrombopoietic growth factors. Blood. 2007; 109: 4607-16
|
|
|
|
|
|
18) Kuter DJ. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med. 2009; 60: 193-206
|
|
|
|
|
|
19) Nurden AT, Viallard JF, Nurden P. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Lancet. 2009; 373: 1562-9
|
|
|
|
|
|
20) Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007; 357: 2237-47
|
|
|
|
|
|
21) Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 373: 641-8
|
|
|
|
|
|
22) Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, random-ised, phase 3 study. Lancet. 2011; 377: 393-402
|
|
|
|
|
|
23) Tomiyama Y, Miyakawa Y, Okamoto S, et al. Six month treatment of low dose eltrombopag is efficacious in Japanese patients with refractory chronic immune thrombocytopenic purpura (ITP). Blood. 2009; 114: 541-2. Abstract 1324
|
|
|
|
|
|
24) Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008; 371: 395-403
|
|
|
|
|
|
25) Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009; 113: 2161-71
|
|
|
|
|
|
26) Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010; 363: 1889-99
|
|
|
|
|
|
27) Kuter DJ, Mufti GJ, Bain BJ, et al. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood. 2009; 114: 3748-56
|
|
|
|
|
|
28) Bussel JB, Buchanan GR, Nugent DJ, et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia (ITP). Blood. 2011; 118: 28-36
|
|
|
|
|
|
29) Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombo-cytopenia. Blood. 2011; 117: 4190-207
|
|
|
|
|